# Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

- Source: PR Newswire M&A
- Published: 2026-11-04T21:05:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/nuvation-bio-reports-third-quarter-2026-financial-results-and-provides-business-update-302929623.html
- Canonical: https://groundlevelnews.com/story/nuvation-bio-reports-third-quarter-2026-financial-results-and-provides-abd42d/

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._